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ABSTRACT
Neisseria meningitidis, Haemophilus influenzae, and Moraxella catarrhalis are pathogenic bac-
teria adapted to reside on human respiratory mucosal epithelia. One common feature of
these species is their ability to target members of the carcinoembryonic antigen-related cell
adhesion molecule (CEACAM) family, especially CEACAM1, which is achieved via structurally
distinct ligands expressed by each species. Beside respiratory epithelial cells, cells at the
dentogingival junction express high levels of CEACAM1. It is possible that bacterial species
resident within the oral cavity also utilise CEACAM1 for colonisation and invasion of gingival
tissues. From a screen of 59 isolates from the human oral cavity representing 49 bacterial
species, we identified strains from Fusobacterium bound to CEACAM1. Of the Fusobacterium
species tested, the CEACAM1-binding property was exhibited by F. nucleatum (Fn) and
F. vincentii (Fv) but not F. polymorphum (Fp) or F. animalis (Fa) strains tested. These studies
identified that CEACAM adhesion was mediated using a trimeric autotransporter adhesin
(TAA) for which no function has thus far been defined. We therefore propose the name
CEACAM binding protein of Fusobacterium (CbpF). CbpF was identified to be present in the
majority of unspeciated Fusobacterium isolates confirming a subset of Fusobacterium spp. are
able to target human CEACAM1.
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Introduction
The mucosal pathogens Neisseria meningitidis
(meningococci, Nm), Haemophilus influenzae (Hi),
and Moraxella catarrhalis (Mx) are human-specific
organisms commonly resident in the nasopharynx of
healthy individuals. However, for reasons still not
fully known, Hi and Mx can cause a number of
localised infections including sinusitis, otitis media,
and exacerbations of chronic obstructive pulmonary
disease (COPD). In addition, Nm and occasionally
Hi and Mx may disseminate from the nasopharynx
to cause serious infections such as septicaemia and
meningitis [1–4].
Studies of potential targets on host cells for adhe-
sion have led to the discovery that antigenically dis-
tinct adhesins of these three species are able to target
members of the human carcinoembryonic antigen-
related cell adhesion molecules (CEACAMs [5–7]).
The meningococcal and related N. gonorrhoeae (Ng)
CEACAM-binding ligands, the Opa proteins, have
been studied extensively [7–10]. In the case of Hi,
the outer membrane proteins P5 and P1, with β-
barrel structures, have been shown to bind to the
receptors [6,11,12]. However, in the case of Mx, the
CEACAM-binding ligands are the ubiquitous surface
proteins A1 (UspA1) and A2V (UspA2V), a trimeric
autotransporter adhesin (TAA) [5,13,14]. The term
autotransporter was initially used to describe the solu-
ble IgA protease from Ng [15]. All autotransporters,
a protein superfamily of Gram-negative bacteria, share
the common features of an N-terminal signal sequence
and a C-terminal β-barrel forming domain, which
facilitates passage of the passenger domain across the
outer membrane [16]. Unlike the monomeric-secreted
autotransporters such as IgA proteases, the passenger
domain of trimeric autotransporters often remain
attached to the surface of the bacterial cells where
they perform diverse adhesive functions (reviewed in
[17]). TAAs were first proposed to be a subfamily of
autotransporters [18] but are now considered to be
a distinct protein family of the autotransporter super-
family [17]. Despite the initial nomenclature of auto-
transporter continuing to be used, we now know
a number of other proteins have roles to play in the
surface presentation of such proteins [reviewed in 19].
The CEACAM family belongs to the
Immunoglobulin superfamily and include epithelial
and polymorphonuclear cell-expressed members
such as CEACAM1, CEACAM3, CEA, CEACAM6,
and CEACAM8 whose distribution in tissues and
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functions may be divergent [20,21]. Of the cell sur-
face-expressed members of the family, CEACAM1
(previously known as BGP and CD66a) has the
broadest tissue distribution and is expressed on the
apical surfaces of epithelial cells of human mucosa,
cells of myeloid lineage as well as on some endothelial
cells [20–22]. Focussing specifically on oral/respira-
tory tissues, CEACAM expression on normal epithe-
lial cells in oral, tonsillar, and lung tissues has been
reported [22–24]. We have demonstrated the expres-
sion of the receptor on the apical surfaces of tonsillar
epithelium [25], where the receptor may be available
for microbial colonisation. Since increased receptor
density demonstrably increases the chances of cellular
invasion by bacteria [26], these observations suggest
that CEACAMs may play a critical role in mucosal
colonisation and pathogenesis. CEACAM1, CEA, and
CEACAM6 are expressed in human junctional
epithelium [27]. However, whether other oro-
respiratory bacterial colonisers/pathogens besides
Nm, Hi, and Mx target CEACAMs has not been
fully investigated.
In this study, we undertook a survey of oral bacteria
and from a screen of oral isolates comprising 20 genera
and at least 51 individual species of bacteria, we identi-
fied that strains belonging to the Fusobacterium genus,
Gram-negative anaerobic bacteria, were capable of bind-
ing to CEACAM1. Further, we show that two distinct
species, F. nucleatum (Fn) and F. vincentii (Fv), as well
as several unspeciated clinical isolates of Fusobacterium
bind to CEACAM1. Historically, Fn and Fv were mem-
bers of the same species (F. nucleatum), however, recent
studies have since shown the distinction between the
species based on whole-genome similarity [28,29]. The
interaction of Fusobacterium spp. with CEACAM1 is
mediated by a trimeric autotransporter which we have
named CbpF. Identification of surface proteins of
Fusobacterium involved in pathogenesis may ultimately
lead to novel therapeutic strategies to eliminate the
numerous diseases caused by these bacteria.
Materials and methods
Bacterial strains and culture
A comprehensive list of bacterial species and strains
used in this study is provided (Tables S1 and S2). The
collection consisted of clinical isolates and type strains
as detailed. The control isolates of N. meningitidis
(C751) and M. catarrhalis (MX1) used in the study
have been described previously [5,10].
To culture oral species, fastidious anaerobe agar
(supplied by LabM, Heywood, UK) supplemented
with 10% horse blood was inoculated and grown
under anaerobic conditions (N2:CO2:H2 8:1:1 in
a Don Whitley MkIII Anaerobic Cabinet, Bingley,
UK) for 2–3 days at 37°C. Bacteria were subcultured
into fastidious anaerobe broth media (LabM), and in
the case of the Prevotella, Porphyromonas,
Flavobacterium, Bacteroides, and Campylobacter spe-
cies, the medium was supplemented with hemin
(5 μg ml−1), and grown under the same conditions.
Antibodies
Polyclonal antiserum against a 15-mer peptide
(KW15) corresponding to residues 255–269 of Fn
CbpF (KNDYKDANDIDVNKW) was raised in rabbits
using standard protocols. Anti-polyhistidine mouse
monoclonal antibody was purchased from Qiagen
(Manchester, UK) and used at 0.2 μg ml−1. YTH71.3
was purchased from AbDSerotec (Oxford, UK) and
Kat4c was purchased from Dako UK Ltd,
Cheadle, UK.
Preparation of bacterial lysates
Bacterial cells were harvested by centrifugation
(12,000 g, 15 min). The pellet was resuspended in
phosphate buffered saline (PBS) containing protease
inhibitor cocktail [1 mM phenylmethylsulphonyl
fluoride (PMSF), 1 µM E-64, 1 µM pepstatin A,
6 nM bestatin, and 100 µM EDTA; PIC]. Bacterial
suspensions were lysed by freeze-thaw, aliquots were
solubilised in SDS-NaOH, and their optical densities
were measured at 260 nm to allow standardisation as
described previously [30].
Immunodotblotting
Soluble CEACAM1-Fc constructs and control CD33-
Fc constructs used have been described previously
[5,10,31]. For analysis of CEACAM binding by
immunodotblotting, equivalent amounts of bacterial
lysate were immobilised on to nitrocellulose mem-
branes. Non-specific binding sites were blocked with
3% bovine serum albumin (BSA) in PBS containing
0.05% Tween 20 (PBST; 1 h, Room Temperature
(RT)). The membranes were then overlaid with either
CEACAM1-Fc, CEACAM1 N-domain construct
(N-Fc), CEACAM1 I91A mutant construct, or CD33-
Fc negative binding control for 1 h, RT (1–2 μg ml−1
as indicated in 1% BSA-PBST). Blots were washed
three times (PBST containing 0.9% w/v NaCl) and
overlaid with anti-human-Fc antibody conjugated to
alkaline phosphatase (AP) in 1% BSA-PBST (1 h,
RT). Following washing, the binding of the recep-
tor–antibody complex to bacterial lysates was
detected by incubation with nitroblue tetrazolium
(NBT) and 5 bromo-4 chloro-3-indolyl phosphate
(BCIP) in AP buffer (100 mM Tris-base, 100 mM
NaCl, 5 mM MgCl2). The relative levels of receptor
binding were determined by densitometric analysis
using the NIH Scion Image program.
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SDS-PAGE and western blotting of Fusobacterial
lysates
Fusobacterial lysates were subjected to sodium dodecyl
sulphate–polyacrylamide gel electrophoresis (SDS-
PAGE, 5–10%) under reducing conditions (180 V, up
to 1 h, RT). Gels were either stained with Coomassie
brilliant blue or the proteins transferred to nitrocellu-
lose or PVDF membranes (300 mA, 1 h, 4°C). Non-
specific binding sites were blocked using 3% BSA in
PBST (1 h, RT). The membranes were overlaid with
CEACAM1-Fc or control constructs (1 µg ml−1) and
receptor binding was detected as described in
immunodotblotting.
Immunoprecipitation of the Fusobacterial ligand
with CEACAM1 N-Fc
To capture the bacterial CEACAM-binding ligand,
100 µl of protein A (50% slurry) coupled to sepharose
CL-4B (Sigma, Gillingham, UK) was incubated with
either 50 µg of N-Fc or the control construct CD33-Fc
overnight at 4°C and subsequently washed three times
with PBSB (Dulbecco’s complete PBS, Fisher Scientific,
Loughborough, UK) to remove any unbound receptor.
Simultaneously, overnight cultures of bacteria were sus-
pended in 100 mM octyl-β-D-glucopyranoside (OG;
final concentration) in PBSB containing PIC. Samples
were mixed end-over-end overnight at 4°C. Insoluble
bacterial material was removed by centrifugation at
10,000 g for 15 min. Soluble supernatant was divided
in two 500 μl aliquots and incubated with either N-Fc or
CD33-Fc receptor–Protein A sepharose complexes for
3 h at 4°C. After washing three times with 50 mM OG
and PBSB, samples were dissociated at 100°C for 10min
in SDS-PAGE dissociation buffer and analysed by elec-
trophoresis and Western blotting.
Identification of CEACAM-binding ligand of
Fusobacterium nucleatum by MALDI-TOF and
N-terminal sequencing
The area of the gel corresponding to the
CEACAM-binding ligand identified by Western
blotting was excised and subjected to in-gel trypsin
digestion. The resulting peptides were analysed by
matrix-assisted laser desorption ionisation time-of-
flight (MALDI-TOF) mass spectrometry, carried
out by the University of Bristol Proteomics
Facility (http://www.bristol.ac.uk/biochemistry/pro
teomics/). The spectra of the tryptic digestion pro-
ducts were acquired using a PE Biosystems
Voyager-DE STR MALDI-TOF mass spectrometer.
Peak lists were analysed using PROFOUND pep-
tide-mapping program (Rockerfeller University).
Following transfer to PVDF membrane, proteins
were detected with Coomassie Brilliant blue and the
ligand band excised and subjected to Edman degrada-
tion to determine the N-terminal sequence, carried out
by the University of Bristol Proteomics Facility.
Treatment of Fusobacterial lysates with formic
acid
As several trimeric autotransporters have been shown
to readily dissociate in formic acid [32], whole-cell
lysates of F. nucleatum were incubated overnight in
70% (v/v) formic acid at RT in the dark. Samples
were subsequently freeze-dried to remove the volatile
formic acid and resuspended in sample buffer prior
to electrophoresis and Western blotting. Western
blots were probed with soluble CEACAM1-Fc and
control constructs as described above.
PCR and sequencing
Genomic DNA was extracted from Fn isolates using
a DNeasy Tissue Kit (Qiagen) according to the manu-
facturer’s instructions. The cbpF genes were amplified
using CbpF primers For1/Rev1 (Table S3) and purified
using a PCR cleanup kit (Qiagen). Genes were sequenced
through the DNA sequencing service (http://www.dna
seq.co.uk), using appropriate forward and reverse pri-
mers to ensure coverage (Table S3). Sequence analysis
and alignment were performed using Lasergene EditSeq,
SeqBuilder, andMegAlign softwares. Sequence data have
been submitted to the GenBank database under acces-
sion numbers JQ922431–JQ922439.
Generation of recombinant CbpF
CbpF primers For3/Rev2 were used to amplify the
cbpF gene encoding amino acids 7–395 of the mature
protein from clinical isolate 2B3 and cloned into
pQE30UA (Qiagen) according to the manufacturer’s
instructions. Additionally, the pOPINE vector was
used for the generation of recombinant CbpF from
Fn ATCC 25586 (group I; CbpF primers For5/Rev5)
and from the clinical strain 2B3 (group II; CbpF
primers For6/Rev6). Ligation-independent cloning
(LIC) was employed for creating the pOPINE-based
plasmid using the In-Fusion® cloning kit (Clontech,
Saint-Germain-en-Laye, France). Primers for these
constructs are detailed in Table S3.
The pQE30-based plasmids were transformed
into E. coli strain M15 previously transformed with
pREP4 regulation plasmid according to the manu-
facturer’s instructions (Qiagen). The pOPINE-based
expression vectors were transformed into Rosetta™
(DE3) pLacI cells (Novagen, WI, USA). M15 trans-
formants were grown in the presence of 100 μg ml−1
ampicillin and 25 μg ml−1 kanamycin. Rosetta™ cells
were grown in the presence of 100 μg ml−1 ampicil-
lin and 34 μg ml−1 chloramphenicol.
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A 10-ml LB broth culture containing the appropriate
antibiotics was inoculated with the transformed
expression strain and grown overnight at 37°C. Five-
hundred millilitres LB broth containing the relevant
antibiotics then was inoculated using the overnight
culture and grown to late log phase (~OD600 1.8). In
order to induce protein expression, isopropyl thiogalac-
topyranoside (IPTG) was added to a final concentration
of 1 mM. Following 1 h induction, bacteria were col-
lected by centrifugation (6,000 g for 15 min) and pellets
stored at −80°C for subsequent protein purification.
Bacterial pellets were thawed and 5 ml lysis buffer was
added per gram wet weight of pellet (lysis buffer 50mM
NaH2PO4, 300 mM NaCl, 10 mM imidazole). Bacteria
were lysed by sonication on ice and insoluble material
was collected by centrifugation at 10,000 g for 30 min at
4°C. Recombinant proteins were purified from the
supernatant by binding to Ni-NTA resin columns
(Qiagen) washed with wash buffer (lysis buffer contain-
ing 100 mM imidazole) and eluted with elution buffer
(lysis buffer containing 250 mM imidazole). Protein-
containing fractions were exhaustively dialysed against
PBS, assayed for protein content using the Pierce BCA
protein assay (Fisher Scientific, Loughborough, UK),
and stored at 4°C for further analysis.
ELISAs
ELISA plates (96 well, Dynex, Chantilly, USA) were
coated with recombinant CbpF (rCbpF; 3 pmol) in car-
bonate buffer pH 9.5 by overnight incubation at 4°C.
Wells were blocked with 3% w/v BSA (diluted in PBS-T;
PBS with 0.05% v/v TWEEN® 20, Sigma, Gillingham,
UK) for 1 h. Triplicate wells were incubated with the
relevant CEACAM-Fc construct diluted in 1% BSA (w/v
in PBS-T) for 1 h at RT, where the final concentrations
are detailed where required. Following a minimum of
three washes with PBS-T, the AP-conjugated anti-IgG Fc
secondary antibodywas then incubated for a further hour
before three more wash steps. Plates were developed
using SigmaFast™ p-Nitrophenyl phosphate substrate
(Sigma) and absorbance was measured at 405 nm
(A405). Data underwent background subtraction and
standardisation for graphical presentation.
CEACAM-Fc generation
CEA-Fc and mouse CEACAM1b-Fc were purchased
from Sino Biological, Wayne, USA. CEACAM1-Fc,
CEACAM3-Fc, CEACAM6-Fc, CEACAM8-Fc,
CEACAM1 ΔN-Fc, and N-Fc were constructed and pur-
ified using methods as previously described [33]. The
CEACAM1 mutants were constructed using site-
directed mutagenesis from a CEACAM1-3 (containing
N-A1-B1 domains) construct within the pINFUSE2 vec-
tor (NEB; shuttle vector to create Fc fusion proteins). The
vectors were sequenced to confirm the mutation and
transiently transfected into COS1 cells before purifying
protein using Protein A affinity chromatography.
Primers for these constructs are detailed in Table S4.
Results
Fusobacterium nucleatum-CEACAM binding
identification from a panel of oral pathogens
A range of bacterial species associated with the human
oral cavity (Table S1) were screened for CEACAM1
binding in receptor overlay experiments. Bacterial
lysates were standardised as described in Experimental
Procedures and equal amounts were dotted onto nitro-
cellulose membranes. Samples were overlaid with
CEACAM1-Fc, comprising all extracellular CEACAM1
domains fused to the human immunoglobulin G (IgG)
Fc domain (or CD33-Fc used as a control), and binding
subsequently detected using anti-Fc secondary antibo-
dies conjugated to AP. Of the isolates screened initially,
the strongest positive CEACAM1 binding was displayed
by the obligate anaerobe Fusobacterium vincentii (Fv;
Figure 1; Data showing comparable detection of
CEACAM1-Fc and CD33-Fc as well as representative
immunodotblot data are shown in Figure S1).
The nature of CEACAM-binding by F. nucleatum
N. meningitidis, H. influenzae, and M. catarrhalis, all
target CEACAM1 via antigenically variable ligands, how-
ever, all are capable of binding via the IgV-like N-domain
of CEACAM1. To elucidate whether this was the case for
Fusobacterium, bacterial lysates dotted onto nitrocellu-
lose were overlaid with a chimeric construct comprising
CEACAM1 N-domain and human IgG Fc (N-Fc).
Binding of the N-Fc construct to Fv was observed con-
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Figure 1. Densitometric plot of CEACAM1-Fc binding to oral
bacterial species. Bacterial isolates were standardised by
spectrophotometry, applied to nitrocellulose, and overlaid
with CEACAM1-Fc (1 μg ml−1). Mx: CEACAM-binding
UspA2V expressing M. catarrhalis strain MX1 (positive con-
trol), Nm: Opa negative variant N. meningitidis strain C751
(negative control), Fnv: Fusobacterium vincentii. Means and
standard errors of six independent experiments are shown.
*p < 0.001.
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firming that, in common with the ligands of other
respiratory pathogens, the N-domain of CEACAM1
alone is capable of supporting Fv binding (Figure 2;
Representative immunodotblot data and Fc construct
comparisons are shown in Figure S2). Previous studies
have identified a common overlapping region on the
CFG face of CEACAM1 N-domain which supports the
interaction of diverse ligands from Mx, Nm, Ng, and Hi
strains and involves isoleucine at position 91 in each case.
On substitution of isoleucine 91 with alanine at this face
of CEACAM1, binding of these four bacterial species was
abrogated [10,34,35]. Interestingly, Fv was not able to
bind to the I91A CEACAM1-Fc mutant construct indi-
cating the same or overlapping region on CEACAM1 is
also targeted by fusobacteria (Figure 2). No binding of
the CD33-Fc control protein was observed.
Identification of the of Fusobacterium
CEACAM1-binding ligand
Whole cell Fv lysate was subjected to SDS-PAGE
and corresponding Western blots overlaid with
CEACAM1-Fc. A high molecular weight protein of
Fv can be observed binding to CEACAM1 at
~150 kDa that was not present in controls that used
CD33-Fc (Figure 3(a)). In addition to Fv, a second
species (nucleatum; Fn) was also shown to bind to
CEACAM1-Fc in Western blot overlay (Figure 3(b)),
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Figure 2. CEACAM1 N-domain binding to F. vincentii.
Densitometric plot of Fnv overlaid with CEACAM1 (CC1-Fc),
CEACAM1 N-domain (N-Fc), CEACAM1 I91A construct (I91A-Fc),
or CD33 construct (CD33-Fc) used as a negative control.
All constructs were overlaid at 2 μg ml−1. Mean values and
standard errors of three independent experiments are shown.
*p < 0.05.
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Figure 3. Identification of the CEACAM-binding ligand of F. nucleatum and F. vincentii following Western blotting and co-
immunoprecipitation. Western blot of Fv (a) of Fnn (b) under non-reducing conditions overlaid with CEACAM1-Fc (lane 1) or
CD33-Fc (lane 2; both 1 μg ml−1) and detected via an appropriate secondary antibody conjugated to AP. CEACAM1 binding to
a band of ~150 kDa was observed to be present in lane 1 but no binding was observed in the CD33-Fc control (lane 2). (c)
Coomassie stained gel showing co-precipitated proteins from octyl glucoside extracts of Fn and Fv using CD33-Fc or CEACAM-Fc
as indicated. A band of ~150 kDa was co-precipitated with CEACAM1-Fc but not CD33-Fc for each subspecies as indicated (*).
(d) Corresponding Coomassie stained Western blot of Fv co-precipitated using either CD33 or CEACAM1-Fc constructs. The band
indicated (*) represents the CEACAM1-binding ligand of Fv and was subsequently subjected to N-terminal sequencing.
Representative data from one of three repeated experiments are shown.
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suggesting the ability to target CEACAMs is not
restricted to members of the vincentii species.
In order to identify the CEACAM1-binding ligand,
type strains of F. vincentii ATCC 49256 and in
addition F. nucleatum ATCC 25586 were used in co-
precipitation studies as complete genome sequences
are available for both these strains aiding peptide
searches in the NCBI databases for the purposes of
protein matching.
Co-precipitation of the Fusobacterium ligand with the
receptor was carried out using the N- domain of
CEACAM1 (N-Fc) construct (~50 kDa) due to similar
size of the full-length CEACAM1-Fc and the bacterial
ligand (~150 kDa). Co-precipitation with N-Fc yielded
a protein of ~150 kDa not only from Fv, but also from Fn
(Figure 3(c)). It is worth noting that the co-precipitated
ligand(s) were eluted and separated under reducing con-
ditions yet retain the molecular weight of ~150 kDa,
suggesting either the ligand was a single protein or
a stable multimer not containing cysteine residues. In
addition, the ligand of Fn appears slightly larger than
that of Fv indicative of some sequence variation between
these proteins. No CEACAM-binding protein was
observed in controls where CD33-Fc was used in place
of N-Fc (Figure 3(c)). The protein co-precipitated with
CEACAM1-Fc was subjected to in-gel tryptic digestion
and subsequent analysis by MALDI-TOF mass spectro-
metry. This proved unsuccessful with a paucity of pep-
tides released by the in-gel digestion even when the
amount of starting material was regarded as sufficient.
N-terminal sequencing of the CEACAM1-binding
ligand of F. nucleatum and F. vincentii
CEACAM1 N-Fc co-precipitated protein from both Fv
(Figure 3(d)) and Fn (not shown) were blotted onto
polyvinylidene fluoride (PVDF) membrane, stained
with Coomassie and Sequenced by Edman degradation.
For Fn, the sequence of AAPVIKAGTAT was returned
which corresponded to the Fn protein FN1499 (accession
number AAL93625). For Fv, a different N-terminal
sequence was returned (VPVIQGG) and corresponded
to the Fv protein FNV1729 (accession number
EAA24952). Despite possessing dissimilar N-terminal
sequences, the two proteins are 88.8% identical over the
whole gene products (Figure S3). Due to the lack of
defined function, no nomenclature has been previously
described for these proteins, which we have referred to as
CEACAM binding proteins of Fusobacterium (CbpF).
Properties of the CEACAM-binding protein of
Fusobacterium, CbpF
CbpFof Fn andFv are 479 and471 amino acid residues in
length, respectively. Both proteins possess similar 24 resi-
due signal sequences (identified by SignalP; http://www.
cbs.dtu.dk/services/SignalP/; version 3.0) yieldingmature
proteinswith a predictedmolecularmass of 48,209Da for
Fn and 47,348Da for Fv. The disparity between the size of
the CEACAM-binding ligand on Western blots
(~150 kDa) and mature CbpF (~50 kDa) is therefore
suggestive of a trimeric molecule. The slightly larger size
of FN1499 fits well with the observed sizes of Fn and Fv
ligands following CEACAM co-precipitation (Figure 3
(b)). BLAST analysis of CbpF identified conserved
domains typically found within the TAA family of pro-
teins. In addition to CbpF, the CEACAM-binding ligand
ofM. catarrhalis, UspA1 is also a trimeric autotransporter
protein forming a stable trimeric coiled region within
which the CEACAM-binding domain is located [36].
Besides matching FN1499 and FNV1729 by BLAST as
expected, three other fusobacterial proteins were identi-
fied with homology to CbpF within type strains namely
FNP_1391 (accession numberEDK89173.1,
F. polymorphum, 644 amino acids, E = 9e-68), FN0735
(accession number NP_603632, Fn, 617 amino acids
E = 2e-65), and FN0471 (accession number NP_603368,
Fn, 340 amino acids, E = 4e-58). Identities of all five
fusobacterial proteins are shown in Figure S4. Whilst
the proteins identified to bind CEACAM1 share the
closest similarity, the presence of other homologues sug-
gest thatmultiple variants of this trimeric autotransporter
are present in Fusobacterium species.
Using a search engine designed to identify and
annotate domains within trimeric autotransporter
adhesins [daTAA; 37], graphical representations of
the domain arrangement of CbpF homologues were
generated and are shown in Figure 4.
Full details of the TAA domains annotated are pro-
vided in the reference describing daTAA [37]. Domains
pertinent to CbpF of Fn and Fv include YadA-like head
domains, a left handed β-helix present in a number of
trimetric autotransporters, including Yersinia spp. The
domain possesses a highly conserved, relatively hydro-
phobic, SSAFG-like sequence likely to form the internal
surface of a trimeric β-roll head. A neck region appears to
link the head to a stalk lacking extensive coiled coil (in the
case of TAAs three strands of α-helix which further coil
around each other) observed in other TAAs such as
UspA1 of M. catarrhalis but possesses short regions
flanking the predicted β-barrel membrane anchor.
Graphical representations of YadA and UspA1 are also
shown for comparative purposes (Figure 4). A coiled-coil
search usingMARCOIL [38] also showedno evidence for
the presence of coiled coils in the predicted stalk region.
Immunological relatedness of Fv and Fn CbpFs
and evidence for their trimeric nature
In order to validate that FN1499/FNV1479 represented
CbpF, rabbit polyclonal antiserum was raised against
a 15-mer peptide corresponding to residues 255–269 of
Fn CbpF KNDYKDANDIDVNKW (KW15). This pep-
tide was also conserved in CbpF of Fv representing
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residues 240–254. Anti-KW15 serum was bound to the
co-precipitated CEACAM ligand of Fn as well as Fv
(Figure 5(a)). Although the CEACAM-binding ligand
of M. catarrhalis (UspA1) is a stable trimer, it can be
dissociated into apparent monomers by heating for
>5 min in SDS-sample dissociation buffer. This appears
not to be the case for CbpF, unlike other autotransporters
such as UspA1 and BadA, we did not observe ladder-like
partial denaturation during electrophoresis [14,39]. In
order to try to dissociate CbpF intomonomeric subunits,
whole cell lysates of Fn were solubilised in 70% formic
acid which we have successfully used for other autotran-
sporters previously [40]. Following lyophilisation to
remove formic acid, samples were run on SDS-PAGE
and corresponding Western blots overlaid with anti-
KW15 and CEACAM1-Fc
(Figure 5(b)). Following treatment with 70% formic
acid, a band of ~50 kDa can be seen binding anti-KW
15 compared the oligomeric form of the protein in the
absence of formic acid. In contrast to the antiserum,
CEACAM1 only binds to oligomeric CbpF and not the
monomers generated by formic acid treatment. This
suggested the region for CEACAM-binding was depen-
dent on a folded protein conformation.
In order to examine the presence of CbpF in other
species of Fusobacterium, Western blots of lysates from
Fn, Fv, Fp, and also a second Fv strain (ATCC51190)
(Fv2; historically called F. nucleatum subsp. fusiforme)
were overlaid with either CEACAM1-Fc or anti-KW
15. The migration of anti-KW15 binding proteins was
identical to that of the CEACAM-binding proteins of
Fn, Fv, and Fv2, however, no anti-KW15 or
CEACAM-binding was observed for Fp (Figure 6(a)),
indicating that, in addition to Fn and Fv, an identical
CbpF is present in Fv2. Further, no CEACAM1 or
anti-KW15 binding was observed to the
F. animalis-type strain, NCTC12276 (Fa; not shown).
The presence of the cbpF gene was assayed by PCR
using template DNA from Fn, Fv, Fp, Fv2, and Fa
(Figure 6(b)). Products were observed of the expected
size for Fn, Fv, and Fv2, however, no product was seen
for Fp or Fa. Thus Fn, Fv, and Fv2 were shown to
possess a CEACAM1-binding CbpF by PCR and pro-
teomic analysis in contrast to Fp and Fa. Analyses of
CbpF have been confined to immunodotblot and
Western blot in this study, however surface expression
of CbpF by Fv was confirmed using anti-KW15
(Figure S5).
Presence and sequence similarity of CbpF in
clinical isolates of Fusobacterium spp
Data suggest that CbpF is present in at least two of
the five historical Fn subspecies. In order to deter-
mine the extent of CbpF expression in
Fusobacterium, a panel of clinical isolates of mostly
unspeciated Fusobacterium spp. (Figure 7(a); Table
S2) was screened for CEACAM1 binding. Of the
FN1499 FN0471 FN0735FNV1729 FNP1391 UspA1 YadA
*
Figure 4. Identities and domain organisation of CbpF-like autotransporters from Fusobacterial spp. Domain annotation models
of the family members indicating number of YadA-like head unit repeats and stalk coiled-coil regions relative to another
CEACAM-binding autotransporter UspA1. Models of both UspA1 and YadA are included for comparative purposes. The
approximate location of the KW15 epitope is indicated in FN1499 (*).
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unspeciated Fusobacterium isolates, 18 out of the 31
strains examined (58.1%; see Figure 7(a) for exam-
ples) bound to CEACAM1 whilst 13 isolates dis-
played no CEACAM1 binding. In addition, the
presence of the cbpF gene was examined by PCR
(Figure 7(b)). The majority of strains that displayed
CEACAM1 binding produced a gene product of
~1,500 bp by PCR. Of the non-binding strains, the
majority lacked a gene product of appropriate size by
PCR suggesting the gene may be absent. Hence, these
isolates may be more akin to Fp or Fa. However, two
non-binding isolates did give an appropriately sized
PCR product (2B24 and 2B28, not shown), but the
reasons for these isolates not binding to CEACAM1
remain to be elucidated. Indeed, not all strains of
a species may express a protein for a number of
reasons including phase variation which has been
suggested for other autotransporters of
Fusobacterium spp. [41]. Neither strain identified as
Fusobacterium spp. (2B31 and 2B35) bound
CEACAM1, nor did F. periodonticum (2B36). These
findings highlight the presence of cbpF and its gene
product CbpF are specifically within some, but not
all, Fusobacterium species.
Sequencing of CbpF from clinical isolates
In order to compare sequences of CbpF from clinical
isolates, a number of strains were selected and PCR
products were generated using the primers A and
B (see experimental procedures). Sequences were
obtained for strains 2B2, 3, 4, 8, 9, 13, 16, 17, and
32 (sequence alignments obtained together with Fn
and Fv CbpF are shown in Figure S6). Overall
sequence similarities suggest two main groups of
related sequences with group I including 2B13,
2B17, 2B32, Fn, and Fv (87.7–99.8% sequence iden-
tity). Group II comprises 2B2, 2B3, 2B4, 2B8, 2B9,
and 2B16 (90.3–100% sequence identity; Figure S7).
Between the groups, the sequence identity varies
between 77.0 and 82.1%. Whilst differences do exist
throughout the sequence, the main difference
between the two groups appears to be in the number
of YadA-like head domains within CbpF, with group
II possessing a greater number (at least 14) compared
with group I (at least 8). Overall, group II CbpF
members are larger than Group I CbpF by ~45
amino acids. Such differences in size were detectable
in a CEACAM1 overlay by Western blot in which
group II CbpF migrated at a higher molecular mass
than group I CbpF (Figure 7(c)). The difference in
sequence between group I and group II was validated
using LC MS/MS. No identification of co-precipitated
2B3 was initially made from the existing database.
Only when sequence data from 2B3 was added was
a positive match obtained, indicating this sequence
differed from group I CbpF and was not in the
database (Figure S8). Hence, group II appears to
represent a hitherto unrecognised subdivision of
autotransporters within Fusobacterium.
Recombinant CbpF–CEACAM1 interactions
Recombinant CbpF was produced from Fn ATCC
25586 and the 2B3 isolate, spanning amino acids
from the passenger domain only, to represent
groups I and II, respectively. The resulting recombi-
nant proteins lack the β-barrel translocator domain
but possess all the YadA-like head domains as well as
the putative stalk domain.
+FA -FA
Anti-KW15 
O
M
+FA -FA
CEACAM1
CC1 CC1PAS PAS
Fn Fva
b
*150 kDa - *
250 kDa -
100 kDa -
75 kDa -
50 kDa -
100 kDa -
75 kDa  -
50 kDa -
Figure 5. Immunological reactivity of anti-KW15 antiserum
with co-immunoprecipitated proteins and proteins solubilised
using formic acid. (a) Western blot showing binding of anti-
KW15 antiserum to the protein co-precipitated using
CEACAM1 (CC1) compared to the control co-precipitation
which used protein A-sepharose (PAS) alone. Bands were
observed at ~150 kDa (*) for both Fn and Fv as indicated.
(b) Fn lysate treated with or without formic acid (FA) prior to
electrophoresis and Western blotting. The blots were overlaid
with anti-KW15 antiserum. Anti-KW15 bound to both
a 150 kDa oligomeric (O) band and a 50 kDa monomeric
protein band (M), whilst CEACAM1 only bound to the oligo-
meric form of CbpF. Data are representative of two indepen-
dent experiments.
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The protein produced (from 2B3) was able to bind
CEACAM1-Fc in a dose-dependent manner up to
2 μg ml−1 both by ELISA (Figure 8) and by immuno-
dotblotting (not shown). This recombinant protein was
able to bind CEACAM1 in both monomeric and tri-
meric forms; however, increased binding was apparent
to the trimeric form of the protein (Figure S9). Whilst
the current study has focussed on CEACAM1, CbpF
also has the ability to bind to CEA (Figure S10), albeit to
a varying degree with the group I protein displaying
significantly less binding compared to group II CbpF,
about 50% as well. Moreover, the CbpF from group II
displayed significantly higher binding to CEACAM1-Fc
than group I CbpF, though the difference was not as
great, about 75%. Neither class of CbpF showed the
ability to bind other CEACAM constructs including
CEACAM3-Fc, CEACAM6-Fc, CEACAM8-Fc, or
murine CEACAM1b (mCEACAM1b-Fc; Figure 9).
In keeping with other bacterial pathogens studied
to date which bind to CEACAM1 [5,6,10], binding
could be inhibited by the N-domain binding antibody
YTH71.3 (Figure 10). Examination of CEACAM1-Fc
IgV-like domain mutants confirmed that residues on
the CFG face of CEACAM1 were critical for
adhesion. Mutating the residues F29 or Q44 to
amino acids found naturally in other CEACAMs
consistently reduced adhesion to background
(Figure 11(a)). For reference, the relative positions
of the mutated amino acids are indicated in Figure
11(b).
These data indicate that the passenger domain of
CbpF contains the CEACAM-binding motif as might
be expected and appears to share an overlapping bind-
ing region on the N-domain of CEACAM1 with other
pathogenic bacterial CEACAM-binding ligands.
Functional recombinant CbpF will facilitate future
studies on the precise nature of CEACAM–CbpF
interactions.
Discussion
Here we report that Fusobacterium binds to human
CEACAM1 via a trimeric autotransporter which we
have named CbpF. This protein exists as a ~50 kDa
subunit but runs as a stable trimer during electrophor-
esis and Western blotting. Other reported adhesins for
Fn include RadD, a putative autotransporter protein
implicated in arginine-dependent interspecies interac-
tions and biofilm formation of Fn [42]. A small α-
helical protein FadA has been demonstrated to target
human vascular endothelial cadherin and subsequently
enables endothelial tight junction penetration by Fn and
other species [43]. Fn species also express a porin,
FomA which has been shown to bind to statherin [44]
and also the human immunoglobulin Fc region [45].
Given our CEACAM1 construct was conjugated to
150kDa
1  2 3 4
* * *
*
* *
Anti-KW15 Pre-bleed serum
CEACAM1-Fc CD33-Fc
150kDa
1  2 3 4
1 2 3 41 2 3 4
a
1500bp
 Fn  Fv  Fp Fv2b  Fa
Figure 6. Comparison of CbpF presence in Fusobacterium species. (a) Western blots of lysates of Fusobacterium species nucleatum (Fn
lane 1), vincentii (Fv lane 2), polymorphum (Fp lane 3), and a second vincentii strain (formerly F. nucleatum subspecies fusiforme (Fv2
lane 4)) were overlaid with anti-KW15, control pre-bleed serum, CEACAM1-Fc, and CD33-Fc as indicated. Note the CEACAM1-Fc and
anti-KW15 binding bands in Fn, Fv, and Fv2 (*) but not in Fp. (b) PCR of cbpF from F. spp. Note the ~1,500 bp product for Fn, Fv, and
Fv2 but no product as expected for Fp or Fa. Data are representative of two independent experiments.
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human IgG-Fc, there was potential for IgG- Fc-FomA
binding to occur. Initial studies identified CEACAM1-
Fc binding in Fv. No fomA gene appears to be present
in the genome for ATCC 49256, the strain of Fv used in
this study, thus expression of FomA may vary between
strains. Using equivalent amounts of CEACAM1-Fc
and CD33-Fc, we always observed CEACAM1-Fc bind-
ing to be higher than that of the control protein in
immunodot blots, Western blots and ELISA-based
assays employed in this study. In addition, commer-
cially available CEA (which lacks Fc) bound to CbpF
(Figure S10) and the CEACAM N-domain specific
antibody YTH71.3 blocked the CbpF–CEACAM1-Fc
interaction. CbpF therefore appears to specifically target
CEACAMs as do other TAAs such as UspA1 and
UspA2V expressed by M. catarrhalis [5,14].
Little sequence identity was found to exist between
CbpF and the other known CEACAM-binding ligands
of diverse bacterial species including the type-1 fim-
briae of E. coli and Salmonella typhimurium, shown to
bind to oligosaccharides on CEACAMs [46] or the
Afa/Dr family proteins of E. coli [47]. Inhibition of
CbpF–CEACAM1-Fc binding by YTH71.3 suggest Fn
targets the same region of the non-glycosylated face of
CEACAM1 targeted by Opa, P5, and UspA proteins
[10,35,36].
The diverse adhesive functions of the trimeric
autotransporter family are conveyed by the passen-
ger domain of these proteins [reviewed in 19]. We
produced recombinant CbpF passenger domain
from the clinical strain 2B3 and Fn ATCC 25586
lacking the β-barrel (which can lead to solubility
issues) and lacking the signal peptide (to prevent
cleavage of the N-terminal His tag needed for pur-
ification). Recombinant CbpF migrated predomi-
nantly in monomeric form following heating,
unlike native CbpF expressed by fusobacterial spe-
cies. The decreased tendency to oligomerise could be
attributed to the truncated form of the recombinant
molecule lacking the β-barrel region of the protein.
CEACAM binding to the monomeric form of CbpF
was evident in Western blot overlays. Heat alone is
sufficient to convert some TAAs to monomeric form
such as UspA1 of M. catarrhalis [48]. Others includ-
ing UspA2 of M. catarrhalis have been denatured
using formic acid [32]. Unlike the CbpF monomer
produced using formic acid, monomeric recombi-
nant CbpF was able to bind to CEACAM1-Fc. This
suggests formic acid exposure resulted in the loss of
a conformational epitope still present within the
monomeric recombinant even after SDS-PAGE and
Western blotting. This is in contrast to the
a
b
1500bp
150kDa
1 2 3 4
150kDa
c
100kDa
50kDa
Figure 7. Analyses of CEACAM1 binding and cbpF gene
presence in clinical isolates of F. nucleatum. (a) Western
blot of representative clinical Fn isolates overlaid with
CEACAM1-Fc. Strain designations are indicated above
each lane. Note the absence of binding for 2B6 compared
to the other isolates which expressed a ~150 kDa
CEACAM1-binding protein. (b) PCR for cbpF from represen-
tative clinical isolates. Strain designations are indicated
above each lane. Note the lack of product for isolate 2B6
corresponding with a lack of CEACAM1 binding observed
in A. (c) Analysis of CbpF migration from the two distinct
phylogenetic groups. Western blot overlay indicating the
relative migration of CbpF from group I (lane 1 and 4) and
group II (lane 2). Lane 1, 2B17, lane 2 2B16, lane 3 2B14
(non-binding control), and lane 4 2B13. Blot was overlaid
with CEACAM1-Fc at 1 μg ml−1 and detected via an alka-
line phosphatase-conjugated secondary antibody. Data are
representative of two independent experiments.
-0.5
0
0.5
1
1.5
2
2.5
0 0.5 1 1.5 2 2.5
CEACAM1-Fc concentration (µg.ml-1)
A
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5
Figure 8. Recombinant CbpF–CEACAM1 interaction. Recom-
binant CbpF protein was immobilised on ELISA plates and
overlaid with CEACAM1-Fc (Black diamonds) or the
corresponding I91A mutant (grey squares) Binding was
detected using an appropriate alkaline phosphatase-conju-
gated secondary antibody and chromogenic substrate. Data
shown are means of three independent experiments ± SD.
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observations made with the CEACAM1 binding
TAAs of M. catarrhalis, UspA1 and UspA2V,
which retain the ability to bind to CEACAM even
following treatment with formic acid [14]. Overall
CbpF–CEACAM interaction appears, therefore, to
be more dependent on conformation than the
CEACAM-binding UspA proteins of M. catarrhalis.
We confirm that in keeping with other TAAs, the
adhesive function of CbpF resides in the passenger
domain.
Sequencing of CbpF from a number of
Fusobacterium clinical isolates revealed two distinct
groups (I and II) which differed mainly in the number
of head repeat regions. Assays to detect binding to
other CEACAMs (CEACAM1, 3, 5, 6, 8, and murine
CEACAM1) only showed demonstrable binding for
both group I and II CbpFs to CEACAM and CEA.
While group II CbpF was bound CEA and CEACAM1
to the same level, group I CbpF favoured CEACAM1
showing significantly reduced binding compared to
CEA (Figure 9).
The phenylalanine at position 29 and glutamine at
position 44 on the CFG face of CEACAM1 are the
only two unique residues shared between CEACAM1
and CEA, F29 is also found in CEACAM3, whilst
Q44 is not found in any other CEA-family member.
Altering the F29 and Q44 residues to naturally occur-
ring alternatives found within other CEACAMs com-
pletely disrupts binding (Figure 11). Additionally,
mutants from other areas on the CFG face were
shown to negate adhesion, such as Y34, G47, Q89,
and I91. Interestingly, Q89N displayed reduced, but
higher than background, levels of adhesion to group
II CbpF and no binding at all to group I. The higher
binding of V96A mutant to CbpFII compared to
CbpFI could implicate V96 in the CbpF binding sur-
face on CEACAM1. However, no significant differ-
ence was observed between V96A and CC1-Fc in
binding to recombinant CbpFI or CbpFII. As the
IgV-like N-terminal domain of all CEACAMs is
highly conserved, and that CbpFs have only been
seen to bind CEACAM1 and CEA, this suggests that
these proteins have specifically evolved to target these
proteins while avoiding other highly similar receptors
such as CEACAM3. This is contrary to UspA1 for
example, which has been shown to bind to
0.00
0.20
0.40
0.60
0.80
1.00
1.20
CC1-Fc CC3-Fc ΔNCC1-FcCEA-Fc mCC1-Fc Ab
A
40
5
CEACAM-Fc variant (10 pmol.ml-1)
***
***
***
***
CC6-Fc CC8-Fc
CbpF I
CbpF II
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Figure 9. Recombinant CbpF interactions with different CEACAMs. Of purified CbpFI (ATCC25586) and CbpFII (2B3) (3 pmol)
immobilised onto ELISA plates. Subsequently, 1 pmol of each CEACAM-FC variant were used followed by an anti-human
secondary antibody to detect binding. Each CEACAM-FC conjugate contained all the extracellular IgC- and IgV-like domains
except for the ΔN mutant that lacked the N-terminal IgV-like domain. A secondary antibody negative control (Ab) was included.
Mouse CEACAM1b (mCC1-Fc) and CEACAM8 (CC8-Fc) were also used as these have not previously been shown to bind any
human pathogen adhesins. Three independent replicates are shown ± SD. A one-way ANOVA (F 15ð Þ ¼ 370:8; p<0:0001)
followed by a post-hoc Tukey HSD test identified significant differences between CEA and CEACAM1 (***p<0:0001) for CbpF
I and II. Both CC1-Fc and CEA bound to CbpF I and II significantly more than all other CEACAM constructs used (p<0:0001).
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CEACAM3 and -6 as well as CEACAM1 and -5
[49,50]. This could allow CbpF to avoid activating
neutrophils where CEACAM3 is exclusively located,
where CEACAM3 induction can lead to
a proinflammatory effect via its immunoreceptor tyr-
osine-based activation motif (ITAM)-like domain
[49,51].
The lack of a conserved CEACAM-binding motif
between bacterial species render an in silico identi-
fication of the CEACAM-binding domain of CbpF
redundant. Based on previous experience of
CEACAM-binding ligands, it is not always the
most conserved region of the protein within each
species which is responsible for CEACAM binding.
For example, the more diverse regions of Opa resid-
ing within two surface-exposed loops mediate neis-
serial interaction to CEACAMs [52]. Conversely, in
the case of UspA1 proteins, a critical ~20 amino acid
region within the coiled-coil stalk mediates
CEACAM1 binding [36]. Within the published gen-
ome of Fn ATCC 25586, two other putative TAAs
were identified, FN0471 and FN0735. Differences in
the sequences of FN0471 and FN1321 may be useful
in aiding the elucidation of the CEACAM-binding
region of CbpF. However, if the corresponding
proteins are not expressed, sequence comparison is
meaningless. Within our strain collection, two
strains (2B24 and 2B28) produced a PCR product
with CbpF primers (although slightly larger than the
products for type-I and type-II CbpF) yet did not
bind CEACAM1. Besides differences in sequence,
one potential explanation for strains 2B24 and
2B28 proteins lacking CEACAM binding is phase
variation.
In CbpF, we observed antigenic variation with
a number of insertion/deletion events comparing
the size of the head between group I and group II
CbpF as well as individual amino acid changes.
F. nucleatum has a very low GC content of ~27%
[53] containing numerous polymeric nucleotide
tracts which could lead to phase variation of
genes. Whilst potential phase variation of other
autotransporters of F. nucleatum has been
described [41], to date no studies have demon-
strated phase variation in F. nucleatum TAAs.
Therefore, future studies will compare the
sequences of CbpF and related homologues with
their expression levels and their ability to bind to
CEACAM1.
F. nucleatum appears to have a uniquely adap-
table role in interactions with both the host and
other microbes. It is an important component of
dental plaque due to a promiscuous ability to coag-
gregate with many different species of oral bacteria
[54]. Fn is often portrayed in the literature as
a secondary coloniser and an important link in
biofilm establishment [55]. Fn is a commonly iso-
lated periodontal pathogen from clinical infections
at other body sites including bacteraemia, amniotic
fluid as well as intestinal tissue associated with
inflammatory bowel disease [56–58]. Such variety
in isolation site suggests that this species has the
capacity to interact directly with diverse human
cells and tissues.
Of interest to these studies is the fact that other
bacterial species able to utilise CEACAMs for adher-
ence also use them for cellular invasion and tissue
penetration; this is the case with N. meningitidis [59].
In addition, CEACAM engagement by bacterial
pathogens leads to reduced epithelial shedding [60].
Notably, Helicobacter pylori has recently been shown
to engage human CEACAM1 via the surface protein
HopQ [33,61,62]. Engagement of HopQ facilitates the
translocation of the virulence factor CagA into host
cells promoting a proinflammatory response [62].
The identification of the CEACAM1-binding
TAA expressed by a subset of Fusobacterium iso-
lates will enable the role of CbpF in disease to be
studied in more detail. Such studies may be of
particular importance to cancer as fusobacterial
species have been associated with colorectal cancer
and resistance to therapies [63,64]. Fusobacterium
has also been associated with oral carcinomas [64].
Through better understanding of the defined inter-
actions in such disease processes, future studies
may inform potential therapeutic strategies to
reduce the global burden of disease caused by
~150kDa -
1 2 3 4 5
2B3
Figure 10. Inhibition of N-Fc binding to a clinical isolate of Fn.
Lysate 2B3was separated by SDS-PAGE using 5% trenchwell gels.
Following Western blotting, strips were but and overlaid with
CEACAM1 N-Fc alone (0.2 μg ml−1; lane 1), in the presence of
YTH71.3 (anti-CEACAM N-domain antibody raised in rat,
10 μg ml−1; lane 2), in the presence of control antibody Kat4c
(anti-CEACAM antibody raised in mouse not recognising N-Fc,
10 μg ml−1; lane 3). Lane 4 strip was overlaid with CEACAM1
N-Fc (0.2 μg ml−1; lane 1) in the presence of a rat isotype control
antibody. Lane 5 strip was overlaid with CD33-Fc (0.2 μg ml−1) as
a negative control. Receptor binding was detected using anti-
human-Fc conjugated to alkaline phosphatase and developed
using NBT/BCIP. N-Fc binding to both clinical isolates was com-
pletely inhibited in the presence of YTH71.3 but not the control
antibody Kat4c or the rat isotype control. Image is representative
of two independent experiments.
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Fusobacterium spp. but also those other pathogens
that require interaction with this organism to aid
colonisation and subsequent pathology.
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